|Mr. Claude Solitario||Managing Director, CEO & Director||141.6k||N/A||N/A|
|Ms. Melanie Jaye Leydin C.A., B.Bus, CA||Joint Company Sec. & Director||141.63k||N/A||1973|
|Ms. Renee Stanton-Horne||Operations & Account Mang.||N/A||N/A||N/A|
|Ms. Stephanie Ottens||Investor Relations Director||N/A||N/A||N/A|
|Mr. Josh Purdy||PR Director||N/A||N/A||N/A|
|Dr. Michael Player||Head of Research||N/A||N/A||N/A|
|Dr. Matthew Flax||Head of Algorithm Devel. Team||N/A||N/A||N/A|
|Mr. Archie Defillo M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Jennifer Solitario||Sr. VP of Corp. Health||N/A||N/A||N/A|
|Mr. Massimiliano Grassi||Head of Artificial Intelligence||N/A||N/A||N/A|
Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.
Medibio Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.